Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma

Authors

  • S.V. Prylutska Joint Ukrainian-German Center on Nanobiotechnology, Taras Shevchenko National University of Kyiv, Kyiv 01601, Ukraine
  • O.V. Lynchak Joint Ukrainian-German Center on Nanobiotechnology, Taras Shevchenko National University of Kyiv, Kyiv 01601, Ukraine
  • V.V. Kostjukov Belgorod State University, Belgorod 308015, Russian Federation
  • M.P. Evstigneev Belgorod State University, Belgorod 308015, Russian Federation
  • O.V. Remeniak National Pirogov Memorial Medical University, Vinnytsya 21018, Ukraine
  • V.K. Rybalchenko Joint Ukrainian-German Center on Nanobiotechnology, Taras Shevchenko National University of Kyiv, Kyiv 01601, Ukraine
  • Yu.I. Prylutskyy Joint Ukrainian-German Center on Nanobiotechnology, Taras Shevchenko National University of Kyiv, Kyiv 01601, Ukraine
  • U. Ritter Joint Ukrainian-German Center on Nanobiotechnology, Technical University of Ilmenau, Ilmenau 98693, Germany
  • P. Scharff Joint Ukrainian-German Center on Nanobiotechnology, Technical University of Ilmenau, Ilmenau 98693, Germany

DOI:

https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-2.13030

Keywords:

C60 fullerene, cisplatin, hematological indices, Lewis lung carcinoma, tumor-bearing mice survival, С60-Cis-Pt nanocomplex

Abstract

Summary. Background: Cisplatin (Cis-Pt) is a widely used anticancer drug but its therapeutic efficiency is limited by hemato-, cardio-, hepato-, nephro- and neurotoxicity. Complexation of Cis-Pt with C60 fullerene nanoparticle will allow to enhance the antitumor activity of the drug and to reduce its side toxic effects. Aim: To estimate the antitumor effects of С60-Cis-Pt nanocomplex in Lewis lung carcinoma (LLC) and analyze hematological toxicity in tumor-bearing mice. Materials and Methods: Complexation of C60 fullerene and Cis-Pt molecule was studied by computer simulation. С60-Cis-Pt nanocomplex was i.p. injected to LLC-bearing mice in a total dose of 7.5 mg/kg (C60:Cis-Pt as 3.75:3.75 mg/kg). The survival of tumor-bearing mice and the relative reduction of tumor weight was recorded. Blood indices were determined using the Particle Counter PCE­210 automatic hematology analyzer. Results: Computer simulation demonstrated the formation of С60-Cis-Pt nanocomplex in physiological medium and its stability due to the hydrophobic interactions. Treatment with C60-Cis-Pt nanocomplex increased survival time of LLC-bearing mice by 32%, normalized hemoglobin content (up to 100 g/l), erythrocyte and platelet count as compared to the untreated LLC-bearing mice. Tumor weight decreased by 35.5%; the mitotic index of tumor cells decreased by 78%, and apoptotic index increased by 75%. The revealed effects of the C60-Cis-Pt nanocomplex were more pronounced than the effects of Cis-Pt or C60 fullerene alone in equivalent dose. Conclusion: Treatment with C60-Cis-Pt nanocomplex prolonged the survival of LLC-bearing mice and reduced anemia in LLC-bearing mice.

References

Florea AM, Büsselberg D. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel) 2011; 3: 1351–71.

Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189–207.

Greish K. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting. Methods Mol Biol 2010; 624: 25–37.

Duan X, He C, Kron SJ, Lin W. Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016; 8: 776–91.

Wagstaff AJ, Brown SD, Holden MR, et al. Cisplatin drug delivery using gold-coated iron oxide nanoparticles for enhanced tumour targeting with external magnetic fields. Inorg Chim Acta 2012; 393: 328–33.

Min Y, Mao C-Q, Chen S, et al. Combating the drug resistance of cisplatin using a platinum prodrug based delivery system. Angew Chem Int Edit 2012; 51: 6742–47.

Mejri A, Vardanega D, Tangour B, et al. Encapsulation into carbon nanotubes and release of anticancer cisplatin drug molecule. J Phys Chem B 2015; 119: 604–11.

Liang X-J, Meng H, Wang Y, et al. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci USA 2010; 107: 7449–54.

Chaudhuri P, Paraskar A, Soni S, et al. Fullerenol cytotoxic conjugates for cancer chemotherapy. ACS Nano 2009; 3: 2505–14.

Niu Y, Yan C. The effect of fullerenol combined with cisplatin on the proliferation of cervical cancer Hela cells. J Cancer Ther 2016; 7: 232–8.

Foley S, Crowley C, Smaihi M, et al. Cellular localisation of a water-soluble fullerene derivative. Biochem Biophys Res Commun 2002; 294: 116–9.

Prylutska S, Grynyuk I, Grebinyk S, et al. Сomparative study of biological action of fullerenes C60 and carbon nanotubes in thymus cells. Mat-wiss u Werkstofftech 2009; 40: 238–41.

Johnston HJ, Hutchison GR, Christensen FM, et al. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol Sci 2010; 114: 162–82.

Russ KA, Elvati P, Parsonage TL, et al. C60 fullerene localization and membrane interactions in RAW 264.7 immortalized mouse macrophages. Nanoscale 2016; 8: 4134–44.

Larner SF, Wang J, Goodman J, et al. In vitro neurotoxicity resulting from exposure of cultured neural cells to several types of nanoparticles. J Cell Death 2017; 10: 1–7.

Franskevych D, Palyvoda K, Petukhov D, et al. Fullerene C60 penetration into leukemic cells and its photoinduced cytotoxic effects. Nanoscale Res Lett 2017; 12: 40.

Gonchar OO, Maznychenko AV, Bulgakova NV, et al. C60 fullerene prevents restraint stress-induced oxidative disorders in rat tissues: possible involvement of the Nrf2/ARE-antioxidant pathway. Oxidative Med Cell Longevity 2018; 2018: 2518676.

Tabata Y, Murakami Y, Ikada Y. Photodynamic effect of polyethylene glycolmodified fullerene on tumor. Jpn J Cancer Res 1997; 88: 108–16.

Ji ZQ, Sun H, Wang H, et al. Biodistribution and tumor uptake of C60(OH)x in mice. J Nanopart Res 2006; 8: 53–63.

Zhu J, Ji Z, Wang J, et al. Тumor-inhibitory effect and immunomodulatory activity of fullerol C60(OH)x. Small 2008; 4: 1168–75.

Skamrova GB, Laponogov IV, Buchelnikov AS, et al. Interceptor effect of C60 fullerene on the in vitro action of aromatic drug molecules. Eur Biophys J 2014; 43: 265–76.

Prylutskyy YuI, Evstigneev MP, Cherepanov VV, et al. Structural organization of С60 fullerene, doxorubicin and their complex in physiological solution as promising antitumor agents. J Nanopart Res 2015; 17: 45.

Prylutskyy YuI, Cherepanov VV, Evstigneev MP, et al. Structural self-organization of C60 and cisplatin in physiological solution. Phys Chem Chem Phys 2015; 17: 26084–92.

Zakharian TY, Seryshev A, Sitharaman B, et al. A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J Am Chem Soc 2005; 127: 12508–9.

Lu F, Haque SA, Yang ST, et al. Aqueous compatible fullerene-doxorubicin conjugates. J Phys Chem C 2009; 113: 17768–73.

Prylutska SV, Skivka LM, Didenko GV, et al. Complex of C60 fullerene with doxorubicin as a promising agent in antitumor therapy. Nanoscale Res Lett 2015; 10: 499.

Scharff P, Carta-Abelmann L, Siegmund C, et al. Effect of X-ray and UV irradiation of the C60 fullerene aqueous solution on biological samples. Carbon 2004; 42: 1199–1201.

Turov VV, Chekhun VF, Krupskaya TV, et al. Effect of small addition of C60 fullerenes on the hydrated properties of nanocomposites based on highly dispersed silica and DNA. Chem Phys Lett 2010; 496: 152–6.

Grynyuk І, Prylutska S, Slobodyanik N, et al. The aggregate state of C60 fullerene in various media. Biotechnol Acta 2013; 6: 71–6.

Prylutska S, Politenkova S, Afanasieva K, et al. A nanocomplex of C60 fullerene with cisplatin: design, characterization and toxicity. Beilstein J Nanotechnol 2017; 8: 1494–1501.

Kondo A, Maeta M, Oka A, et al. Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice. British J Cancer 1996; 73: 1166–70.

Meng H, Xing GM, Sun BY, et al. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano 2010; 4: 2773–83.

Chaklader M, Das P, Pereira JA, et al. 17-AAG mediated targeting of HSP90 limits tert activity in peritoneal sarcoma related malignant ascites by downregulating cyclin D1 during cell cycle entry. Exp Oncol 2012; 34: 90–6.

Longchar A, Prasad SB. Ascorbic acid (vitamin C) ameliorates cisplatin-induced henatotoxicity in tumor-bearing mice. World J Pharmacy Pharmaceutical Sci 2016; 5: 1870–91.

Fedorchuk OG, Pyaskovskaya OM, Skivka LM, et al. Paraneoplastic syndrome in mice bearing high-angiogenic variant of Lewis lung carcinoma: relations with tumor derived VEGF. Cytokine 2012; 57: 81–8.

Malarczyk E, Kandefer-Szerszeń M, Jarosz-Wilkołazka A. Influence of very low doses of cisplatin on tumor cell proliferation in vitro and some hematological and enzymatic parameters of healthy rats. Nonlinearity Biol Toxicol Med 2003; 1: 123–37.

Ohno S, Strebel FR, Stephens LC, et al. Haematological toxicity of carboplatin and cisplatin combined with whole body hyperthermia in rats. Br J Cancer 1993; 68: 469–74.

Wood PA, Hrushesky WJ. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clinical Invest 1995; 95: 1650–9.

Markovic SD, Zizk JB, Djavic DS, et al. Alteration of oxidative stress parameters in red blood cells of rats after chronic in vivo treatment with cisplatin and selenium. Arch Biol Sci Belgrade 2011; 63: 991–9.

Gharbi N, Pressac M, Hadchouel M, et al. C60 fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett 2005; 5: 2578–85.

Grynyuk I, Grebinyk S, Prylutska S, et al. Photoexcited fullerene C60 disturbs prooxidant-antioxidant balance in leukemic L1210 cells. Mat-wiss u Werkstofftech 2013; 44: 139–43.

Prylutska S, Grynyuk I, Matyshevska O, et al. C60 Fullerene as synergistic agent in tumor-inhibitory doxorubicin treatment. Drugs R D 2014; 14: 333–40.

Franskevych DV, Grynyuk II, Prylutska SV, Matyshevska OP. Modulation of cisplatin-induced reactive oxygen species production by fullerene C60 in normal and transformed lymphoid cells. Ukr Biochem J 2016; 88: 44–50.

Vereshchaka IV, Bulgakova NV, Maznychenko AV, et al. C60 fullerenes diminish the muscle fatigue in rats comparable to N-acetylcysteine or β-alanine. Front Physiol 2018; 9: 517.

Mathew DG, Rooban T, Janani V, et al. Review of paraneoplastic syndromes associated with oropharyngeal squamous cell carcinoma. J Oral Maxillofac Pathol 2010; 14: 41–7.

Prylutska S, Panchuk R, Gołuński G, et al. С60 fullerene enhances cisplatin anticancer activity and overcomes tumor cells drug resistance. Nano Res 2017; 10: 652–71.

Didenko G, Prylutska S, Kichmarenko Y, et al. Evaluation of the antitumor immune response to C60 fullerene. Mat-wiss u Werkstofftech 2013; 44: 124–8.

Skivka LM, Prylutska SV, Rudyk MP, et al. C60 fullerene and its nanocomplexes with anticancer drugs modulate circulating phagocyte functions and dramatically increase ROS generation in transformed monocytes. Cancer Nanotechnol 2018; 9: 8–31.

Asada R, Liao F, Saitoh Y, Miwa N. Photodynamic anti-cancer effects of fullerene [C60]-PEG complex on fibrosarcomas preferentially over normal fibroblasts in terms of fullerene uptake and cytotoxicity. Mol Cell Biochem 2014; 390: 175–84.

Raoof M, Mackeyev Y, Cheney MA, et al. The internalization of C60 fullerenes into cancer cells with accumulation in the nucleus through the nuclear pore complex. Biomater 2012; 33: 2952–60.

Downloads

Published

05.06.2023

How to Cite

Prylutska, S., Lynchak, O., Kostjukov, V., Evstigneev, M., Remeniak, O., Rybalchenko, V., … Scharff, P. (2023). Antitumor effects and hematotoxicity of C60-Cis-Pt nanocomplex in mice with Lewis lung carcinoma. Experimental Oncology, 41(2), 106–111. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-2.13030

Issue

Vol. 41 No. 2 (2019): Experimental Oncology

Section

Original contributions

License

Copyright (c) 2023 Experimental Oncology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.